

Program at a glance

<The 12th Chronic Kidney Disease Frontier Meeting>

February 18 (Sat), 2023	
	12:30-12:35 Opening Remarks
13:00	12:35-13:05 Special Lecture1 Chair: Masanori Abe Speaker: Noritoshi Kato
	13:05-13:55 Oral Presentations1 < Basic1 > Chairs: Takaaki Abe, Hideo Yasuda B-1-01 ~ 04
14:00	13:55-14:35 Sponsored Seminar1 Sponsored by Sumitomo Pharma Co., Ltd. Chair: Yusuke Suzuki Speaker: Yoshinari Yasuda
15:00	14:45-15:35 Oral Presentations2 < Basic2 > Chairs: Ichiei Narita, Hideki Yokoi B-2-01 ~ 04
	15:35-16:25 Sponsored Seminar2 Sponsored by Kyowa Kirin Co., Ltd. Chair: Hirokazu Okada Speaker: Tetsuhiro Tanaka
16:00	16:25-17:15 Oral Presentations3 < Clinical > Chairs: Kunihiro Yamagata, Naoki Tsuboi C-01 ~ 04
17:00	17:15-17:55 Controversy in the Treatment of Glomerulonephritis Part2 Chair: Yusuke Tsukamoto Panelists: Hai An, Roberto Tanchanco, Rosanawati Yahya, Da Yi
18:00	18:00-18:40 Sponsored Seminar3 Sponsored by AstraZeneca K.K. / Ono Pharmaceutical Co., Ltd. Chair: Masaomi Nangaku Speaker: Hitoshi Suzuki
19:00	18:40-19:25 Special Lecture2 Chair: Shoichi Maruyama Speaker: Jonathan Barratt
	19:25- Closing Remarks

Program

12:30-12:35 Opening Remarks

12:35-13:05 Special Lecture1

Chair : Masanori Abe (*Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University, Japan*)

SL1 Diagnosis and treatment of aHUS based on the Japanese clinical guide

Noritoshi Kato

Division of Nephrology, Nagoya University Hospital, Japan

13:05-13:55 Oral Presentations1

“Basic1”

Chairs : Takaaki Abe (*Division of Medical Science, Tohoku University Graduate School of Biomedical Engineering, Japan/ Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Japan*)

Hideo Yasuda (*First Department of Medicine, Hamamatsu University School of Medicine, Japan*)

B-1-01 Activation of fatty acid β -oxidation in proximal tubular epithelial cells is an intrinsic defensive reaction against phosphorus-induced kidney injury

Yusuke Katsuma

Department of Nephrology, Osaka University Graduate School of Medicine, Japan

B-1-02 Neutrophil TBK1 contributes to pathogenesis of glomerulonephritis in acute phase via mediating migration, production of ROS, and degranulation

Takashi Ishide

Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan

B-1-03 Effectiveness of Imatinib for MCTO nephropathy

Toshiaki Usui

Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan

B-1-04 A matrix protein Egfl6 secreted from thick ascending loop of Henle maintains vascular homeostasis

Youngna Kang^{1,2}

¹*Department of Nephrology, Kyoto University Graduate school of Medicine, Japan,*

²*Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan*

13:55-14:35 Sponsored Seminar1

Sponsored by Sumitomo Pharma Co., Ltd.

Chair : Yusuke Suzuki (*Department of Nephrology, Juntendo University Graduate School of Medicine, Japan*)

SS1 Evidence based management for Diabetic Kidney Disease (DKD)

Yoshinari Yasuda

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

14:45–15:35 Oral Presentations2

“Basic2”

Chairs : Ichiei Narita (*Division of Clinical Nephrology and Rheumatology Kidney Research center, Niigata University, Japan*)

Hideki Yokoi (*Department of Nephrology, Graduate School of Medicine, Kyoto University, Japan*)

B-2-01 Hypoxia-inducible lncRNA MIR210HG positively regulates HIF1 α via antagonizing miR-93-5p in renal tubular epithelial cells

Hanako Saigusa

Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Japan

B-2-02 Gut microbiome-derived phenyl sulfate promotes insulin secretion and insulin resistance in DKD patients

Yoshiyasu Tongu

Tohoku University School of Medicine, Japan

B-2-03 TLR7-mediated RNA-sensing system is involved in the pathogenesis of IgA nephropathy

Mingfeng Lee

Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.

B-2-04 Kif26b contributes to the progression of interstitial fibrosis via migration and myofibroblast differentiation in renal fibroblast

Yuta Yamamura

Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan

15:35–16:25 Sponsored Seminar2

Sponsored by Kyowa Kirin Co., Ltd.

Chair : Hirokazu Okada (*Department of Nephrology, Saitama Medical University, Japan*)

SS2 Management of anemia in CKD using HIF-PH inhibitors

Tetsuhiro Tanaka

Department of Nephrology, Rheumatology and Endocrinology, Tohoku University Graduate School of Medicine, Japan

16:25-17:15 Oral Presentations3

“Clinical”

Chairs : Kunihiro Yamagata (*Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan*)

Naotake Tsuboi (*Department of Nephrology, Fujita Health University School of Medicine, Japan*)

C-01 Neuroblastoma suppressor of tumorigenicity 1 (NBL1) and risk of progression to end-stage kidney disease in diabetes

Hiroki Kobayashi^{1,2,3}

¹*Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan,*

²*Section on Genetics and Epidemiology, Research Division, Joslin Diabetes Center, Boston, MA, USA,*

³*Department of Medicine, Harvard Medical School, Boston, MA, USA*

C-02 Variability in Spot Urine Protein-creatinine Ratio Helps Differentiating Membranous Nephropathy from Minimal Change Nephrotic Syndrome

Chiemi Ema

First Department of Medicine, Hamamatsu University School of Medicine, Japan

C-03 Renal artery remodeling and renal renin angiotensin system in chronic kidney disease

Nanako Oshiro

Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Japan

C-04 Changes in body composition in patients undergoing extended-hours hemodialysis with liberalized diet

Yuki Takeda

Department of Nephrology, Nagoya University, Nagoya, Japan

17:15-17:55 Controversy in the Treatment of Glomerulonephritis Part2

Chair : Yusuke Tsukamoto (*Nephrology, IMS Itabashi Chuo Medical Center, Japan*)

Panelists Hai An

Hanoi Medical University, Vietnam

Roberto Tanchanco

Ateneo de Manila University, Philippines

Rosanawati Yahya

Kuala Lumpur Hospital, Malaysia

Da Yi

National University Hospital, Singapore

18:00–18:40 Sponsored Seminar3

Sponsored by AstraZeneca K.K. / Ono Pharmaceutical Co., Ltd.

Chair : Masaomi Nangaku (*Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan*)

SS3 The phenotypic difference of IgA nephropathy and strategy of treatment

Hitoshi Suzuki

Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan

18:40–19:25 Special Lecture2

Chair : Shoichi Maruyama (*Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine, Japan*)

SL2 IgA nephropathy: Past, Present and Future

Jonathan Barratt

University of Leicester, UK

19:25– Closing Remarks